Searched for
GREGG ALTON
Tata Trusts, Gilead sign MoU on viral hepatitis in IndiaUnder the MoU, companies will form a joint program committee to implement activities related to prevention, awareness and education, testin...- Grant of patent will not lead to any increase in sovaldi pricing: Gregg AltonBrushing aside criticism from some experts, Alton tells ET that the grant of the patent will not lead to an increase in the price of the dr...
- Americans want to pop made in India Sovaldi drug for 1 per cent of the costThe drug is showing up for sale alongside illegal goods and narcotics on the dark web, which can be accessed through identity-hiding softwa...
- Mylan launches hepatitis-C Sovaldi tablets in IndiaSovaldi is sold by Mylan's dedicated sales force as part of its Hepato Care segment.
- Patent row no hurdle for Gilead Pharma’s Sovaldi launchGilead Pharma says that the recent decision by the patent office, which rejected patent for one of its molecules, does not impact its India...
- Gilead to challenge hepatitis C drug patent rejection decision"The main patent applications covering sofosbuvir are still pending before the Indian Patent Office," Alton said.
- Hepatitis C medicine being imported for Rs 1 croreThe imported drug comes at around Rs 15 lakh a month, taking the cost to Rs 45-50 lakh for a three-month course.
- Gilead Sciences Inc allows 4 Indian pharmaceutical companies Ranbaxy Laboratories, Matrix Laboratories, Hetero Drugs and Strides Arcolab to sell HIV GenericsRanbaxy Laboratories, Matrix Laboratories, Hetero Drugs and Strides Arcolab can make and sell the three drugs in 100 countries by paying ro...
- US bio-pharma firm Gilead Sciences in pact with four Indian cosUS-based bio-pharmaceutical company Gilead Sciences on Tuesday entered into new licensing pacts with four Indian firms.
- US' Gilead appeals against patent rejection of AIDS drug VireadUS drug company Gilead Sciences has filed an appeal in the Indian Intellectual Property Appellate Board (IPAB) to challenge a recent order ...
- Drug cos to launch anti-Aids medicinePrices of popular anti-Aids medicine Tenofovir could soon fall as several Indian drug companies plan to launch their low-cost versions in t...
- Anti-AIDS blitz sees pharma firms locked in ugly battleIt has now emerged that Aids Healthcare Foundation (AHF), the US-based NGO that accused Cipla of over pricing anti-AIDS drug, Viraday, in I...
- Aids drug prices to fall if Gilead fails to defend patent applicationPrice of a crucial AIDS drug may fall further if Cipla and AIDS patients succeed in their challenge to a patent application filed here by U...
- Gilead to launch generic VireadUS-based biopharmaceutical firm Gilead Sciences on Friday will launch generic versions of its HIV/AIDS drug 'Viread' in the next 3-6 months...
- AIDS drug Tenofovir price set to crashBlockbuster AIDS drug Tenofovir is set to get cheaper after its inventor and US patent holder Gilead struck non-exclusive licensing deals w...
- Gilead’s anti-AIDS drug to cost $1 a day hereViread, the largest selling anti-HIV/AIDS drug in the United States, will be available to patients in India at a special price equivalent o...
Load More
